The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The prefrontal cortex region of the human brain is responsible for a range of complex functions from decision-making to certain types of memory. When something goes wrong in this part of the brain, it can be very detrimental for cognition and behavior.

PerkinElmer Inc (PKI.N) on Monday agreed to sell three of its businesses to private equity firm New Mountain Capital for up to $2.45 billion in cash, as it looks to focus on its life sciences and diagnostics businesses under a new name.

Rising demand for core diagnostics offset better-than-feared declines in COVID-19 test sales, shedding light on the companies’ post-pandemic futures.

Meridian Bioscience said on Friday that the Emergency Use Authorization for its Revogene SARS-CoV-2 molecular test has been reissued by the US Food and Drug Administration.

On July 27, Illumina and KingMed Diagnostics Group Co., Ltd. reached a new strategic cooperation on tumor gene detection.

Hologic reported after the close of the market on Wednesday that declining sales of COVID-19 assays and difficulties obtaining semiconductor chips contributed to an overall 14 percent year-over-year decline in its fiscal third quarter revenues.

BioGX said on Wednesday that it has obtained CE-IVD marking for a point-of-care, multiplex RT-PCR SARS-CoV-2 assay.

On July 28, Innovita Biological Technology Co., Ltd. was listed on the SSE STAR Market with the stock code of 688253. Its issue price was CNY 26.06 per share. After the opening, the market value exceeded CNY 4.6 billion.

AstraZeneca's acquisition of TeneoTwo will give the company access to its clinical-stage T-cell engager, TNB-486, strengthening their hematological cancer pipeline.

Roche’s new test is the first available immunoassay that allows for simultaneous, independent determination of the hepatitis C virus antigen and antibody status.